Results 111 to 120 of about 2,224,846 (160)

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib

CPT: Pharmacometrics & Systems Pharmacology
Insight into the development of treatment resistance can support the optimization of anticancer treatments. This study aims to characterize the tumor dynamics and development of drug resistance in patients with non‐small cell lung cancer treated with ...
Anyue Yin, G. D. Marijn Veerman, Johan G. C. vanHasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, Lena E. Friberg, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Dirk Jan A. R. Moes   +9 more
doaj   +1 more source

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

, 2014
Yosuke Togashi,1 Hidetoshi Hayashi,1–3 Kazuhiko Nakagawa,2 Kazuto Nishio1 1Department of Genome Biology, 2Department of Medical Oncology, Kindai University Faculty of Medicine, 3Department of Medical Oncology, Kishiwada Municipal Hospital, Osaka ...
Nakagawa K, Nishio K, Hayashi H, Togashi Y   +3 more
core  

Correction: Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. [PDF]

Oncoscience, 2021
Solanki HS, Raja R, Zhavoronkov A, Ozerov IV, Artemov AV, Advani J, Radhakrishnan A, Babu N, Puttamallesh VN, Syed N, Nanjappa V, Subbannayya T, Sahasrabuddhe NA, Patil AH, Prasad TSK, Gaykalova D, Chang X, Sathyendran R, Mathur PP, Rangarajan A, Sidransky D, Pandey A, Izumchenko E, Gowda H, Chatterjee A.   +24 more
europepmc   +1 more source

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

, 2010
Noemí Reguart1, Andrés Felipe Cardona2, Rafael Rosell31Medical Oncology Service, ICMHO, Hospital Clinic Barcelona, Barcelona, Spain; 2Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de
Andrés Felipe Cardona, Noemí Reguart, Rafael Rosell   +2 more
core  

GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer. [PDF]

Oncol Lett, 2020
Dong Z, Wang Y, Ding V, Yan X, Lv Y, Zhong M, Zhu F, Zhao P, He C, Ding F, Shi H.   +10 more
europepmc   +1 more source

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer

, 2020
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation.
Guus JJE Heynen (8854577), Emily Chater (9252893), Egbert F Smit (9252899), Rajat Roy (9252896), Olivier E Pardo (9252905), Hongde Li (1930807), Michael J Seckl (9252902), Julian Downward (49269), Yili Hu (1471066), Zhigang Liu (265354), William Stokes (4320334), Huiru Tang (115310), Yulan Wang (50197), Elza de Bruin (594407)   +13 more
core  

Erratum: LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]. [PDF]

Onco Targets Ther, 2021
europepmc   +2 more sources

AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer. [PDF]

Cell Rep
Creixell M, Taylor SD, Gerritsen J, Jiang M, Bae SY, Augustin T, Loui M, Boixo C, Minamino S, Gong V, Creixell P, White FM, Meyer AS.   +12 more
europepmc   +1 more source

Phase II trial of second-line erlotinib and digoxin for nonsmall cell lung cancer (NSCLC)

, 2011
Fadi Kayali, Muhamad A Janjua, Damian A Laber, Donald Miller, Goetz H KloeckerUniversity of Louisville, James Graham Brown Cancer Center, Louisville, KY, USABackground: In vitro digoxin sensitizes cancer cells to the induction of apoptosis by ...
Muhamad A Janjua, Donald Miller, Damian A Laber, Goetz H Kloecker, Fadi Kayali   +4 more
core  

RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model. [PDF]

Signal Transduct Target Ther
Kim S, Kim B, Lim A, Kim H, Cho J.
europepmc   +1 more source